TxCell appoints Damian Marron as Chief Executive

Francois Meyer becomes Executive Chairman of the Board

TxCell, a French biotechnology company developing cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, has appointed Damian Marron as Chief Executive. In addition, Francois Meyer, previously CEO and Chairman of the Board of TxCell become Executive Chairman.

Marron will guide the development of Ovasave, TxCell’s lead autologous Ag-Treg cell-based immunotherapy. Ovasave is currently in Phase II development for the treatment of Crohn’s disease.

'At this stage of TxCell’s development, it has been critical for us to appoint a CEO who has both a high level of experience at working in niche and orphan market places with unmet medical needs, as well as for both private and public companies,' said Meyer.

Previously, Marron was CEO of Cytheris, a clinical stage biotechnology company. Prior to this, he was CEO of Trophos from 2008 to 2012.

He has also been Executive Vice President, Corporate Development at NicOx and has held various business development and operational roles at 3M Pharmaceuticals, Orphan Europe, Rhone-Poulenc-Rorer and Glaxo.

You may also like

Research & Development

TxCell names Lonza as its CAR-Treg cellular product manufacturer

Master Service Agreement signed between Lonza Pharma & Biotech and TxCell for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200)
Research & Development

TxCell Signs inlicensing agreement with Inserm Transfert for novel population of regulatory T cells

TxCell SA, a biotechnology company developing innovative, personalised cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, and Inserm Transfert, on behalf of Inserm, the Nantes University (Nantes, France) and the Nantes CHU, have announced the signature of an exclusive worldwide licensing agreement
Manufacturing

TxCell signs strategic agreement with MaSTherCell to manufacture cell therapy products

Company commits to an ambitious product development schedule with two discovery platforms
Manufacturing

TxCell to cut 26 jobs as it reviews its manufacturing strategy

Will focus on R&D and open a new laboratory close to its headquarters in Sophia Antipolis
Research & Development

TxCell raises around €8m in share placement

Will use proceeds to accelerate T-Cell developments and form partnerships with CMOs
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Subscribe now